The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

Pfizer abandoned the development of danuglipron and plans to focus its efforts on GIPR candidates and other earlier obesity programs.

Scientists at Case Western Reserve University and University Hospitals have made an exciting discovery that may change how we ...

In summary, GLP-1 receptor agonists, originally used to treat diabetes, are now being explored for brain protection. Two ...

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Popular prescription weight-loss drugs called GLP-1 receptor agonists are now frequently used by type 1 diabetes patients, despite limited data on the drugs’ safety and effectiveness in this patient ...